Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis

Rapid exacerbation of neuromyelitis optica after rituximab treatment

(2016) Yongqiang Dai et al.   JOURNAL OF CLINICAL NEUROSCIENCE

MS arising during Tocilizumab therapy for rheumatoid arthritis

(2016) Philippe Beauchemin et al.   Multiple Sclerosis Journal

MS arising during Tocilizumab therapy for rheumatoid arthritis

(2016) Philippe Beauchemin et al.   Multiple Sclerosis Journal

A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis

(2015) X. Xu et al.   Disease Models & Mechanisms

Polysialic acid as an antigen for monoclonal antibody HIgM12 to treat multiple sclerosis and other neurodegenerative disorders

(2015) Jens O. Watzlawik et al.   JOURNAL OF NEUROCHEMISTRY

A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients — A twelve month follow-up

(2015) Tobias Derfuss et al.   JOURNAL OF NEUROIMMUNOLOGY

A single dose of a neuron-binding human monoclonal antibody improves brainstem NAA concentrations, a biomarker for density of spinal cord axons, in a model of progressive multiple sclerosis

(2015) Bharath Wootla et al.   Journal of Neuroinflammation

Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease

(2015) Bharath Wootla et al.   MOLECULAR NEUROBIOLOGY

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2015) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy

(2015) Rui Li et al.   Science Translational Medicine

MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial

(2014) Frank Behrens et al.   ANNALS OF THE RHEUMATIC DISEASES

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Human T helper type 1 dichotomy: origin, phenotype and biological activities

(2014) Francesco Annunziato et al.   IMMUNOLOGY

New antibody approaches to lymphoma therapy

(2014) Tejas Suresh et al.   Journal of Hematology & Oncology

Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein

(2014) François Curtin et al.   mAbs

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients

(2014) Tobias Derfuss et al.   Multiple Sclerosis Journal

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

(2014) P. S. Sorensen et al.   NEUROLOGY

Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica

(2014) Maureen A. Mealy et al.   JAMA Neurology

Anti–IL-17A Treatment Reduces Clinical Score and VCAM-1 Expression Detected by in Vivo Magnetic Resonance Imaging in Chronic Relapsing EAE ABH Mice

(2013) Silvy Mardiguian et al.   AMERICAN JOURNAL OF PATHOLOGY

Natural autoantibodies in the physiology and pathophysiology of the immune system

(2013) Stratis Avrameas et al.   JOURNAL OF AUTOIMMUNITY

Immunosuppressive monoclonal antibody to CD64 from patients with long-term stable multiple sclerosis

(2013) P. Annunziata et al.   JOURNAL OF NEUROIMMUNOLOGY

PDGF is Required for Remyelination-Promoting IgM Stimulation of Oligodendrocyte Progenitor Cell Proliferation

(2013) Jens O. Watzlawik et al.   PLoS One

Human Endogenous Retrovirus Protein Activates Innate Immunity and Promotes Experimental Allergic Encephalomyelitis in Mice

(2013) Hervé Perron et al.   PLoS One

Effect of IL-17A blockade with secukinumab in autoimmune diseases

(2012) Dhavalkumar D Patel et al.   ANNALS OF THE RHEUMATIC DISEASES

Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor

(2012) Iris Navarro-Millán et al.   CLINICAL THERAPEUTICS

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Discovery and mechanism of ustekinumab

(2012) Jacqueline M. Benson et al.   mAbs

CD19 as an attractive target for antibody-based therapy

(2012) Ohad Hammer   mAbs

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo

(2011) Elizabeth Ward et al.   BRITISH JOURNAL OF HAEMATOLOGY

A human IgM signals axon outgrowth: coupling lipid raft to microtubules

(2011) Xiaohua Xu et al.   JOURNAL OF NEUROCHEMISTRY

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

(2011) Grant A Hill-Cawthorne et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation

(2011) Laura Codarri et al.   NATURE IMMUNOLOGY

A Single Dose of Neuron-Binding Human Monoclonal Antibody Improves Spontaneous Activity in a Murine Model of Demyelination

(2011) Aleksandar Denic et al.   PLoS One

Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis?

(2010) Amy E. Lovett-Racke et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes

(2010) J. Watzlawik et al.   GLIA

Structural Basis for the Dual Recognition of IL-12 and IL-23 by Ustekinumab

(2010) Jinquan Luo et al.   JOURNAL OF MOLECULAR BIOLOGY

Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis

(2010) S. Sotgiu et al.   Multiple Sclerosis Journal

Oligoclonal bands still yield clues about multiple sclerosis

(2010) Anne H. Cross et al.   Nature Reviews Neurology

Rituximab-Associated Infections

(2010) Juan C. Gea-Banacloche   SEMINARS IN HEMATOLOGY

Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells

(2009) Sha Mi et al.   ANNALS OF NEUROLOGY

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

(2009) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Monoclonal antibodies in MS: Mechanisms of action

(2009) B. Bielekova et al.   NEUROLOGY

Natural antibodies and cancer

(2009) H. Peter Vollmers et al.   New Biotechnology

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

B-cell-activating factor inhibits CD20-mediated and B-cell receptor-mediated apoptosis in human B cells

(2008) Yohei Saito et al.   IMMUNOLOGY

CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients

(2008) F G Joseph et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY

In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification

(2008) Stefan Steidl et al.   MOLECULAR IMMUNOLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-17 Production in Central Nervous System-Infiltrating T Cells and Glial Cells Is Associated with Active Disease in Multiple Sclerosis

(2007) John S. Tzartos et al.   AMERICAN JOURNAL OF PATHOLOGY